Shots: Boston has entered into a definitive agreement to acquire Baylis for $1.75B up front. The transaction is anticipated to close in Q1’22 The acquisition will bolster Boston’s electrophysiology and […]readmore
Tags : Acquire
Shots: Inotiv to acquire Plato BioPharma for $15.0M that consist of $10.0M in cash, $2.0M in Inotiv’s common shares (57,587) based on the average closing price for 20 trading-day period […]readmore
Shots: Merck to acquire Acceleron for $180/share in cash making a total equity value of ~$11.5B representing a premium of 2.6% to the stock’s closing price. The transaction is expected […]readmore
Shots: Alexion has exercised its option to acquire all remaining equity in Caelum for CAEL-101 which is currently being evaluated in P-III CARES clinical program that consists of 2 P-III […]readmore
Shots: The acquisition includes upfront, milestones, and other consideration payments. Abexxa will continue to operate in the Arlington The acquisition will allow Boehringer to access Abexxa’s expertise and capabilities in […]readmore
Shots: Boston currently holds ~16% equity stake in Devor & acquires the remaining 84% for ~$269M up front and ~$67M upon achievement of clinical & regulatory milestones. The transaction is […]readmore
Shots: ZOLL Medical to acquire all outstanding ordinary shares of Itamar Medical for $31/ADS or $1.03/ordinary share in cash making a total deal value of $538M representing a premium of […]readmore
Shots: Smiths to receive 2.5M at closing in cash and stock which is currently valued at ~$500M, $1.85B in cash along with liabilities & is eligible for up to $100M […]readmore
Shots: Sanofi to acquire Kadmon for $9.50/share in cash making a total equity value of ~ $1.9B with a premium of 79% to a closing price of $5.30 on Sept […]readmore
Shots: Advent and GIC to acquire Sobi for ~$8B (SEK 69.4B) at $27.33/share (SEK 235) representing a premium of 34.5% to the closing price of $20.41. The offer acceptance period […]readmore